These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29633000

  • 21. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib.
    Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F.
    Eur Radiol; 2021 Mar; 31(3):1608-1619. PubMed ID: 32827266
    [Abstract] [Full Text] [Related]

  • 22. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
    Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, Lall C.
    Clin Mol Hepatol; 2014 Jun; 20(2):218-22. PubMed ID: 25032190
    [Abstract] [Full Text] [Related]

  • 23. Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
    Grözinger G, Plentz R, Horger M.
    J Gastroenterol Hepatol; 2013 Mar; 28(3):588. PubMed ID: 23565554
    [No Abstract] [Full Text] [Related]

  • 24. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Mar; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
    Shin SK, Jung YK, Yoon HH, Kwon OS, Kim YS, Choi DJ, Kim JH.
    Korean J Gastroenterol; 2014 Jan 25; 63(1):47-50. PubMed ID: 24463289
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T.
    Int J Cancer; 2017 Sep 01; 141(5):1011-1017. PubMed ID: 28555943
    [Abstract] [Full Text] [Related]

  • 29. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
    Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM.
    Eur Radiol; 2021 May 01; 31(5):2737-2746. PubMed ID: 33123796
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
    Elleuch N, Ennaifer R, Romdhane H, Cheikh M, Hefaiedh R, Bougassas W, Ben Nejma H, BelHadj N.
    Tunis Med; 2015 Jun 01; 93(6):350-2. PubMed ID: 26644095
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
    Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, Kudo M.
    Dig Dis; 2015 Oct 01; 33(6):728-34. PubMed ID: 26488730
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Ippolito D, Querques G, Pecorelli A, Talei Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S.
    J Comput Assist Tomogr; 2019 Oct 01; 43(2):206-213. PubMed ID: 30407241
    [Abstract] [Full Text] [Related]

  • 38. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
    Zhong BY, Ni CF, Chen L, Zhu HD, Teng GJ.
    Radiology; 2017 Aug 01; 284(2):583-592. PubMed ID: 28263701
    [Abstract] [Full Text] [Related]

  • 39. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.
    Eur J Gastroenterol Hepatol; 2013 Feb 01; 25(2):180-6. PubMed ID: 23044808
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.